- Home
- NAUT vs CDXS Comparison
NAUT vs CDXS Comparison
Compare NAUT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- CDXS
- Stock Information
- Founded
- NAUT 2016
- CDXS 2002
- Country
- NAUT United States
- CDXS United States
- Employees
- NAUT N/A
- CDXS N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- CDXS Major Chemicals
- Sector
- NAUT Industrials
- CDXS Industrials
- Exchange
- NAUT Nasdaq
- CDXS Nasdaq
- Market Cap
- NAUT 284.7M
- CDXS 332.0M
- IPO Year
- NAUT N/A
- CDXS 2010
- Fundamental
- Price
- NAUT $1.76
- CDXS $5.28
- Analyst Decision
- NAUT Hold
- CDXS Buy
- Analyst Count
- NAUT 3
- CDXS 2
- Target Price
- NAUT $3.58
- CDXS $11.00
- AVG Volume (30 Days)
- NAUT 172.2K
- CDXS 875.4K
- Earning Date
- NAUT 10-29-2024
- CDXS 10-31-2024
- Dividend Yield
- NAUT N/A
- CDXS N/A
- EPS Growth
- NAUT N/A
- CDXS N/A
- EPS
- NAUT N/A
- CDXS N/A
- Revenue
- NAUT N/A
- CDXS $64,446,000.00
- Revenue This Year
- NAUT N/A
- CDXS N/A
- Revenue Next Year
- NAUT N/A
- CDXS $2.02
- P/E Ratio
- NAUT N/A
- CDXS N/A
- Revenue Growth
- NAUT N/A
- CDXS N/A
- 52 Week Low
- NAUT $1.74
- CDXS $2.53
- 52 Week High
- NAUT $3.46
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- NAUT 30.63
- CDXS 59.97
- Support Level
- NAUT $1.88
- CDXS $5.42
- Resistance Level
- NAUT $2.10
- CDXS $6.01
- Average True Range (ATR)
- NAUT 0.16
- CDXS 0.39
- MACD
- NAUT -0.02
- CDXS -0.05
- Stochastic Oscillator
- NAUT 3.77
- CDXS 46.67
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.